A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer
Status:
Active, not recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This research study is studying a targeted therapy (ML0N128) as a possible treatment for
anaplastic thyroid cancer.
This research study is a Phase II clinical trial. Phase II clinical trials test the safety
and effectiveness of an investigational intervention to learn whether the intervention works
in treating a specific disease. "Investigational" means that the intervention is being
studied. The FDA (the U.S. Food and Drug Administration) has not approved MLN0128 as a
treatment for any disease.
MLN0128 prevents tumor cells from dividing and growing by selectively and potently inhibiting
a chemical, mTOR kinase, which regulates cell growth and survival. Patients with anaplastic
thyroid cancer have been observed to sometimes carry genetic alterations in their tumor cells
which may make the cancer more sensitive to inhibition by MLN0128.
In this research study,the investigators are investigating usefulness of MLN0128 in
metastatic anaplastic thyroid cancer cases.